|
Celgene (CELG): Breakout biotech buy
2008-07-07 05:00:00 Biotechnology player Celgene (http://www.thestockadvisors.co-m/quote.htm?sym=celg) (NASDAQ: CELG (http://www.thestockadvisors.co-m/quote.htm?sym=celg)) is a new buy from Leo Fasciocco (http://www.thestockadvisors.co-m/ccount/click.php?id=2163), whose Ticker Tape Digest (http://www.thestockadvisors.co-m/ccount/click.php?id=2163) focuses on stocks that are breaking out from technical bases. "CELG has broken out from a 3-month flat base and has moved into position to make an all-time high. It just needs to hurdle 75.44. The stock has been one of the best performers in the medical sector having soared from 60 to 69 in the past six years. It is a market leader long-term."CELG markets Thalomid to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat MDS and multiple myeloma. The acquisition of Pharmion gave CELG global rights to Thalomid as well as MDS drug Vidaza. CELG also has discovery capabilities in cell-signaling pathways and stem cell research."CELG has ap...
Biotech experts bet on Celgene (CGNE)
2008-04-25 07:00:00 Two top advisors -- each with a noted expertise in the biotech sector -- have both been long-term fans of Celgene (http://www.thestockadvisors.co-m/quote.htm?sym=celg) (NASDAQ: CELG (http://www.thestockadvisors.co-m/quote.htm?sym=celg)), with both holding the stock in their respective model portfolios. Here, Nate Pile (http://www.thestockadvisors.co-m/ccount/click.php?id=1958), editor of Nate's Notes (http://www.thestockadvisors.co-m/ccount/click.php?id=1958), and John McCamant (http://www.thestockadvisors.co-m/ccount/click.php?id=1959), editor of The Medical Technology Stock Letter (http://www.thestockadvisors.co-m/ccount/click.php?id=1959), each take a look at the long-term prospects for this leading biotech firm.Nate Pile explains, "Now that the Pharmion merger is behind us, it appears that investors are once again recognizing Celgene for what it is – namely, one of the premier stories in the biopharmaceutical space. "As I have said a number of times before, if I could only o...
Biotech expert favors Celgene (CGNE)
2008-01-25 07:00:00 "One of our favorite stock ideas for 2008 is Celgene (quote.htm?sym=celg)(NASDAQ: CELG (quote.htm?sym=celg))," says biotech expert John McCamant (ccount/click.php?id=1620), editor of The Medical Technology Stock Letter (ccount/click.php?id=1620). Here is his review."The company is focused on the development of new and improved treatments for various cancers and other severe, immune, inflammatory conditions, and is well on their way to becoming a major global biopharmaceutical entity. "Over the years, we have watched management consistently deliver on their promises to their shareholders and create additional value. The most notable cancer drugs at CELG are Thalidomide and Revlimid (a second-generation version of Thalidomide)."These are oral therapies that have become the cornerstone in the treatment of multiple myeloma (MM), and which are in clinical development for many other blood-borne cancers, including non-Hodgkin’s lymphoma (NHL) and CLL. "These products are on track...
Celgene (CELG)
2007-08-17 01:48:00 No counting, no zigzags, no motive waves either at this time, just simple beauty, could be called holder paradise or tunneling paradise, that yellow line is simple moving average-200.
By: Just Charts
Cramer Celgene (CELG) Mad Money Picks
2007-08-08 19:43:00 Celgene (CELG) is one of the stocks with the most bullish mentions on Mad Money with Jim Cramer. It has been featured 13 times as a stock to buy in the special section. Cramer has called it a favorite of his and has predicted that it could be a possible takeover target ...see Chart...
Cramer Celgene (CELG) Mad Money Picks
2007-08-06 17:50:00 Celgene (CELG) is one of the stocks with the most bullish mentions on Mad Money with Jim Cramer. It has been featured 13 times as a stock to buy in the special section. Cramer has called it a favorite of his and has predicted that it could be a possible takeover target a total of 3 times as lately as 4/30/2007. Bob Hugin, President and CEO of Celgene has been a guest on Mad Money's "On The Line" segment 3 seperate times, including once on Mad Money's Back to School Tour at University of Virginia's Darden Business School.
By: stockTagger
|
|
 |
|
 |
